Search research articles
Contact Us
Filters
Showing results (131-140 of 141) with videos related to
Page
of 15
Sort By:
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Nature
|
April 10, 2015
SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance
Dohoon Kim, Brian P Fiske, Kivanc Birsoy, et al.
Nature Medicine
|
September 8, 2020
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J Motzer, Paul B Robbins, Thomas Powles, et al.
Cancer Research Communications
|
October 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Dejan Juric, Daniel Anderson, Afshin Dowlati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T K Choueiri, R J Motzer, B I Rini, et al.
The New England Journal of Medicine
|
February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J Motzer, Konstantin Penkov, John Haanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Cell Reports
|
January 21, 2014
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state
Yakov Chudnovsky, Dohoon Kim, Siyuan Zheng, et al.
The Oncologist
|
September 16, 2017
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson, Eric Severson, Laurie Gay, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 141) with videos related to
Sort By:
Page
of 15
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Nature
|
April 10, 2015
SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance
Dohoon Kim, Brian P Fiske, Kivanc Birsoy, et al.
Nature Medicine
|
September 8, 2020
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J Motzer, Paul B Robbins, Thomas Powles, et al.
Cancer Research Communications
|
October 24, 2025
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
Dejan Juric, Daniel Anderson, Afshin Dowlati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T K Choueiri, R J Motzer, B I Rini, et al.
The New England Journal of Medicine
|
February 20, 2019
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J Motzer, Konstantin Penkov, John Haanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Cell Reports
|
January 21, 2014
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state
Yakov Chudnovsky, Dohoon Kim, Siyuan Zheng, et al.
The Oncologist
|
September 16, 2017
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson, Eric Severson, Laurie Gay, et al.
Page
of 15